5 results about "Azelastine" patented technology

Disclosed are pharmaceutical compositions comprising azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin. Also disclosed are methods of using the pharmaceutical compositions to treat patients suffering from Alzheimer's disease or Parkinson's disease.

This invention provides a pharmaceutical composition combining azelastine and methylcobalamin. [Solution] An orally administered pharmaceutical composition is provided, comprising azelastine or a pharmaceutically acceptable salt of azelastine, methylcobalamin, and one or more pharmaceutically acceptable excipients, wherein the pharmaceutical composition is formulated as a capsule, caplet, tablet, or pill configured for oral administration and absorption in the gastrointestinal tract, and the azelastine or a pharmaceutically acceptable salt of azelastine and methylcobalamin are present together in the pharmaceutical composition in a therapeutically effective daily dose for treating Alzheimer's disease or Parkinson's disease in human patients.

This invention belongs to the field of biomedical technology and provides a mussel adhesive protein and azelastine hydrochloride nasal thermosensitive gel, its preparation and application. The mussel adhesive protein and azelastine hydrochloride nasal thermosensitive gel includes an active ingredient and pharmaceutically acceptable excipients. The active ingredient is recombinant mussel adhesive protein mefp-5 subtype and azelastine hydrochloride. The excipients include a thermosensitive polymer, which is mixed with the active ingredient to form a thermosensitive gel system. This invention solves the technical problem that existing single-drug formulations cannot simultaneously provide rapid symptom relief and long-term mucosal barrier repair for allergic rhinitis by combining recombinant mussel adhesive protein mefp-5 subtype with mucosal repair function with azelastine hydrochloride, which has rapid anti-allergic effects. Pharmacodynamic studies have confirmed that the two active ingredients exhibit a significant synergistic effect (CDI < 0.7) in improving allergy symptoms, inhibiting inflammatory responses, and repairing the mucosal barrier.

The application discloses application of a small-molecule drug azelastine in preparation of a medicine for treating sporotrichosis. The application takes abaA gene as a target for finding a new drug, performs batch molecular docking on a small-molecule database which has been approved by FDA and marketed, and screens out azelastine. The azelastine can inhibit Sporothrix globosa and Sporothrix schenckii, can also inhibit phase conversion of the Sporothrix globosa and the Sporothrix schenckii, and has a certain therapeutic effect on sporotrichosis, and is extremely likely to become a promising new drug for treating sporotrichosis. In the research process, it is also found that the small-molecule drug azelastine can have a broad-spectrum bacteriostatic effect. Since the drug is approved for marketing for treating other symptoms, compared with a new compound, a large amount of time and money cost for analyzing pharmacokinetics and pharmacology and toxicology is saved, and the azelastine has great potential as a new drug for treating sporotrichosis.

To provide novel antiviral treatments, pharmaceutical products, and chemicals that can be used to prevent viral infection and / or viral spread in subjects exposed to, infected with, or at risk of viral infection. [Solution] An azelastine compound in an antivirally effective amount for use as an antiviral substance in a pharmaceutical formulation.